China Approves Eli Lilly's Oral GLP-1 Weight-Loss Drug

Source Summary

China has approved orforglipron, an oral GLP-1 weight-loss drug manufactured by Eli Lilly, marking the company's entry into the Chinese market. The approval comes as China faces a projected 630 million overweight or obese adults by 2050.

Why it matters

This approval expands access to oral GLP-1 therapy in a major market and positions Eli Lilly to capture significant revenue from a population facing rising obesity rates.

Read the Source

• Medical Xpress ↗